Table 1.
The basic characteristics of the included studies: ① Progression-free survival (PFS); ② Overall survival (OS); ③ Peripheral neuropathy; ④ Serious adverse events; ⑤ Rash; ⑥ Vomiting. PBO: Placebo.
| Reference | Total cases | Proteasome inhibitors/control | Man/Woman | Median age (years) | Period | Clinical setting | Main Outcomes |
|---|---|---|---|---|---|---|---|
| Goldschmidt, 2017 [14] | 827 | 413/414 | None | None | Jul. 2005 to Jul. 2008 | Bortezomib vs PBO | ①② |
| Dimopoulos, 2018 | 656 | 395/261 | 414/242 | 58 (52–63)/60 (54–64) | Jul. 2014 to Mar. 2016 | Ixazomib vs PBO | ①③④⑤⑥ |
| Dimopoulos, 2020 [16] | 706 | 425/281 | 377/329 | 72 (42–89)/73 (52–90) | Apr. 2015 to Oct. 2018 | Ixazomib vs PBO | ①③④⑤⑥ |
| Gregersen, 2021 [17] | 168 | 82/86 | 96/72 | 60 (53–64)/62 (58–67) | Jan. 2015 to Apr. 2018 | Carfilzomib vs PBO | ④ |
| Yong, 2021 [18] | 141 | 69/72 | 85/56 | 65 (35–80)/69 (48–83) | Feb. 2013 to Sept. 2016 | Carfilzomib vs PBO | ①②④ |
| Rosiñol, 2012 [19] | 257 | 130/127 | 140/117 | 56/56 | Aug. 2009 to Aug. 2011 | Bortezomib vs PBO | ①②③ |
| Rosiñol, 2017 [20] | 179 | 91/88 | 94/85 | 56/59 | Apr. 2006 to Aug. 2009 | Bortezomib vs PBO | ①③ |
| Sonneveld, 2012 [21] | 827 | 413/414 | 500/327 | 57 (31–65)/57 (25–65) | May 2005 to May 2008 | Bortezomib vs PBO | ①②③ |